A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

Clinical trial NCT06994143 · RECRUITING

Trial details

NCT number: NCT06994143
Sponsor: Cullinan Therapeutics Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Rheumatoid Arthritis (RA

Start date: 2025-05-19
Primary completion: 2027-12-30
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.